Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
about
How to manage aspergillosis in non-neutropenic intensive care unit patientsTherapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveVoriconazole-associated cutaneous malignancy: a literature review on photocarcinogenesis in organ transplant recipientsVoriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype.CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics?Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis.Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.Severe acute respiratory syndrome coronavirus replication inhibitor that interferes with the nucleic acid unwinding of the viral helicasePharmacogenomics of antimicrobial agents.Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapySafety of voriconazole and sirolimus coadministration after allogeneic hematopoietic SCT.Pharmacokinetics of voriconazole administered concomitantly with fluconazole and population-based simulation for sequential use.Clinical Analysis of Adverse Drug Reactions between Vincristine and Triazoles in Children with Acute Lymphoblastic Leukemia.Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.In vitro study of the variable effects of proton pump inhibitors on voriconazoleMulticenter study of voriconazole pharmacokinetics and therapeutic drug monitoring.Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.Plasma Voriconazole Estimation by HPLC.Longitudinal Analysis of the Effect of Inflammation on Voriconazole Trough Concentrations.Aspergillus flavus-Induced Brain Abscess in an Immunocompetent Child: Case report.Steady-state pharmacokinetics of oral voriconazole and its primary metabolite, N-oxide voriconazole, pre- and post-autologous peripheral stem cell transplantation.Pharmacogenomics of the triazole antifungal agent voriconazole.Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450.Triazole antifungal agents in invasive fungal infections: a comparative review.Voriconazole in clinical practice.Pharmacokinetics and pharmacodynamics of antibacterials, antifungals, and antivirals used most frequently in neonates and infants.Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review.Intravenous-to-oral switch in antimicrobial therapy: clinical pharmacology considerations and perspectives.Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Pharmacokinetic considerations in treating invasive pediatric fungal infections.PharmGKB summary: voriconazole pathway, pharmacokinetics.Cutaneous Toxicities From Transplantation-Related Medications.Invasive Aspergillus infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations.Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.Determinants of the Magnitude of Interaction Between Tacrolimus and Voriconazole/Posaconazole in Solid Organ Recipients.Efficacy and cost-effectiveness of voriconazole prophylaxis for prevention of invasive aspergillosis in high-risk liver transplant recipients.Impact of cytochrome P450 2C19 polymorphisms on the pharmacokinetics of tacrolimus when coadministered with voriconazole.
P2860
Q26999448-A6B14B95-CE7C-4535-9E42-430D6B581746Q27009221-623A6125-C175-47D3-8765-4C1D40085921Q27012442-D7CD5EB8-BB5B-40AC-B315-F34670B3C892Q33684379-87CEE273-D3B2-403E-9B38-79B13B9BECD0Q33849298-75335520-D063-42A0-BEA4-6255DED0DFFEQ33982372-A23D0825-BD2C-4DC7-ADDA-2CD7F87FB9BDQ34138276-7546904B-49ED-4611-B9BA-61BAF8E6BA32Q34316979-F0462D7B-1D4D-42EE-A341-D7D397B80BB1Q34977413-DE262707-8A5F-4C64-B253-53B1DEAE068AQ35086478-D11BBD4D-A556-4D0F-8293-5E918A500756Q35114591-AEA91958-5C26-4A76-9124-D7D577166D85Q35231368-24401644-D53A-4359-8C17-6950BF1D79DDQ35364006-72E78D24-0983-4686-BC1E-19DE872BE2B3Q35754431-5DEEDDD2-69CF-49F5-AE5E-7421B594D4DCQ35936943-D3363422-1C4F-475E-ADE7-4AFB734A1F6FQ35960842-E5DB1503-3389-47B3-AB95-79339ECF46CBQ36172497-619CEAB3-3803-4E1C-8B2D-3DBDD8497519Q36608562-E65310B1-FC6C-4A44-9D9A-49A6086AD4D5Q36764126-022E8546-51CE-4120-B43E-CAB3A21D92E7Q36887922-03C2B284-AF18-45B0-B3B4-1D7E927FA7E5Q36905195-BAD26CB6-6FE0-4D06-B544-5790108954B5Q36969849-61D7DF17-9579-4B02-BB17-B5DB2024D63EQ37892536-5AC0DDF2-7B5D-43E6-AE9D-AE0B3B944115Q37945308-2EC0FAB1-FF1D-4B4E-8DC1-F16B4541D4CEQ37964703-A567CCC3-268C-48EE-9268-5C5F57AF3AF8Q38061736-D5DAA343-E394-44C2-9FEE-BA4689D67249Q38215682-C16B68D0-A334-43A4-8921-F30C7BA991E7Q38284468-2793C2F7-C42C-4A19-89A6-9D5AB3BDEA11Q38420688-B48BF87D-19E0-40C2-BEE8-948DFB75980DQ38526795-E34C2A08-E4E8-422D-B13C-CBC1133715EBQ38661462-B152D11C-49A0-4C2C-88F9-DC60FDB434C7Q38775809-11448714-93D6-486B-92A6-28F7CB87E6EEQ38816614-6B2640CD-15A2-4A63-802C-A81DEB428138Q38918175-618124A7-545F-4A6D-9382-7F44659902DDQ39269082-919D0385-55D0-4033-80AF-90C46B25CEFEQ39797076-F935748E-D8D0-486F-A815-49C67540955DQ40290020-3EA5F7D1-12BD-4166-A99B-4B12C822DA83Q40322487-E2F9EF88-901C-42F5-B11C-C91D20828823Q40377329-C24A3215-5089-444D-B355-FC6237E7AE80Q41392620-78D4A4C0-437B-4965-B0E1-8B1514D4D46F
P2860
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacokinetics, metabolism a ...... relation to CYP2C19 genotype.
@ast
Pharmacokinetics, metabolism a ...... relation to CYP2C19 genotype.
@en
type
label
Pharmacokinetics, metabolism a ...... relation to CYP2C19 genotype.
@ast
Pharmacokinetics, metabolism a ...... relation to CYP2C19 genotype.
@en
prefLabel
Pharmacokinetics, metabolism a ...... relation to CYP2C19 genotype.
@ast
Pharmacokinetics, metabolism a ...... relation to CYP2C19 genotype.
@en
P2093
P2860
P50
P1476
Pharmacokinetics, metabolism a ...... relation to CYP2C19 genotype.
@en
P2093
Heike Oberwittler
Ina Scholz
Johanna Weiss
Klaus-Dieter Riedel
P2860
P304
P356
10.1111/J.1365-2125.2009.03534.X
P407
P577
2009-12-01T00:00:00Z